A lentivirus-mediated, CMV promoter–driven WT GLB1 gene therapy approach was used to chronically overexpress β-gal in GM1 gangliosidosis patient fibroblasts and compared with an intermittent ERT approach with a single 24-h exposure to rhβ-gal. This evidence concerns the gene GAL and GM1 gangliosidosis.